Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

82P - Exploring the prognostic role of DNA damage sensing deficiency for immune checkpoint blockade in diverse cancer types


10 Sep 2022


Poster session 01


Molecular Oncology

Tumour Site


Yang Shao


Annals of Oncology (2022) 33 (suppl_7): S27-S54. 10.1016/annonc/annonc1037


Y. Shao1, X. Chen2, X. Wu2, Q. Ou2, J. Yin2, X. Wu2

Author affiliations

  • 1 School Of Public Health, Nanjing Medical University, 210000 - Nanjing/CN
  • 2 Geneseeq Research Institute, Nanjing Geneseeq Technology Inc., 210000 - Nanjing/CN


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 82P


Immune checkpoint blockade (ICB) produces durable responses on difficult-to-treat tumors, but its effects are heterogeneous on patients. DNA damage response (DDR) is a network of multiple functional pathways to maintain genomic stability, and mutations in DDR genes are a major determinant of response to ICB. However, only a subset of DDR-altered patients benefit from ICB, and their responses vary across cancer types.


This is a retrospective pan-cancer study. We assessed the prognostic value of pre-defined core DDR pathways in 1571 patients derived from cBioPortal TMB/Immunotherapy datasets. 7417 treatment-naïve Chinese patients that underwent targeted next-generation sequencing were then used to compare genomic profiles between DDR proficient and deficient samples. Furthermore, we calculated the tumor-infiltrating lymphocyte (TIL) scores of 3164 samples derived from TCGA transcriptome datasets to evaluate the tumor environment (TME) with different types of DDR status.


DDR deficient patients from cBioPortal showed significantly higher tumor mutation burden (TMB, p<0.001) and better ICB overall survival (34 vs 17 months, p=0.001) than DDR proficient. Among the DDR pathways, only damage sensing is an independent prognostic factor for the overall survival of ICB treatment (HR, 0.66; 95%CI, 0.44-0.99). The DDR deficient patients account for 14.5% of our Chinese cohort. Their TMB and microsatellite instability (MSI) ratio varied significantly from DDR proficient samples (p<0.001). Comparison between defects in damage sensing and other DDR pathways showed no remarkable difference in TMB and MSI (p=0.879 and 0.082, respectively), but a set of cancer-related genes involved in modulating TME were differentially mutated. In the TCGA datasets, defects in damage sensing but not other DDR pathways are associated with significantly increased TIL scores than DDR proficiency (p= 0.032 and 0.192, respectively).


Damage sensing deficiency is associated with a favorable prognosis of ICB. The underlying mutations may synergistically modulate the TME. The prognostic role of DNA damage sensing may provide insights into current biomarkers and help stratify DDR-deficient patients for ICB treatment.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


Has not received any funding.


Y. Shao, X. Chen, X. Wu, Q. Ou, J. Yin, X. Wu: Financial Interests, Personal, Full or part-time Employment: Nanjing Geneseeq Technology Inc.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.